Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of human-cl rhFVIII, a Newly Developed Human Cell-Line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A.

    Summary
    EudraCT number
    2008-001563-11
    Trial protocol
    DE   BG  
    Global end of trial date
    18 Sep 2012

    Results information
    Results version number
    v1(current)
    This version publication date
    28 Dec 2016
    First version publication date
    28 Dec 2016
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    GENA-01
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT00989196
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Octapharma AG
    Sponsor organisation address
    Seidenstraße 2, Lachen, Switzerland, CH-8853
    Public contact
    Johann Bichler, Octapharma AG, +41 (0)554512177, johann.bichler@octapharma.ch
    Scientific contact
    Johann Bichler, Octapharma AG, +41 (0)554512177, johann.bichler@octapharma.ch
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    Yes
    EMA paediatric investigation plan number(s)
    EMEA-001024-PIP01-10
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    15 Feb 2013
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    18 Sep 2012
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective of the study was to determine the pharmacokinetics (PK) of Human-cl rhFVIII in terms of the human coagulation factor VIII coagulant activity (FVIII:C) and to compare it with the licensed FVIII concentrate Kogenate FS in previously treated patients (PTPs) suffering from severe haemophilia A.
    Protection of trial subjects
    The study was conducted in accordance with the ethical principles of the Declaration of Helsinki, and ICH-GCP, and national regulatory requirements. In- and exclusion criteria were carefully defined in order to protect subjects from contraindications, interactions with other medication and safety factors associated with the investigational medicinal product. Throughout the study safety was assessed, such as occurrence of adverse events, lab values, vital signs and physical examinations. In particular, patients were checked at several pre-specified times whether they had developed an inhibitor to factor VIII.
    Background therapy
    NA
    Evidence for comparator
    In part I of the study, the PK of Human-cl rhFVIII and the licensed comparator product (Kogenate FS) were assessed in a randomized, cross-over, open label manner. In part II, patients who completed Part I were followed up for a period of at least 50 exposure days (EDs) and at least 6 months during which bleeding episodes were treated with Human-cl rhFVIII only.
    Actual start date of recruitment
    27 May 2010
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Bulgaria: 6
    Country: Number of subjects enrolled
    Germany: 6
    Country: Number of subjects enrolled
    United States: 10
    Worldwide total number of subjects
    22
    EEA total number of subjects
    12
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    2
    Adults (18-64 years)
    19
    From 65 to 84 years
    1
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Recruitment period May 2010 - October 2011. In total, 22 evaluable previously-treated patients (PTPs) suffering from severe haemophilia A (FVIII:C ≤1%) were enrolled from 9 study centres in Bulgaria, Germany and the US.

    Pre-assignment
    Screening details
    Severe hemophilia A (FVIII:C <1%), male subjects ≥12 and ≤65 years of age, previously treated with FVIII concentrate, at least 150 EDs, Immunocompetent (CD4+ count >200/μL), Neg. for anti-HIV, if positive viral load <200 particles/μL or <400,000 copies/mL; freely given informed consent; no present or past inhibitor (greater/equal 0.6 BU) to FVIII

    Period 1
    Period 1 title
    Overall trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    No

    Arm title
    Human-cl rhFVIII vs. Kogenate FS (PK cross-over)
    Arm description
    After a FVIII wash-out period of at least 96 hours, subjects received either Human-cl rhFVIII or Kogenate FS (according to the randomisation scheme) for the first PK cycle and the other FVIII product for the second PK cycle. A dose of 50 IU FVIII /kg BW (labelled potency) was administered. PK blood samples for the determination of FVIII levels were taken before and at 0.25, 0.5, 0.75, 1, 3, 6, 9, 12, 24, 30 and 48 hours after the end of the injection.
    Arm type
    Experimental

    Investigational medicinal product name
    Human-cl rhFVIII
    Investigational medicinal product code
    Other name
    Nuwiq
    Pharmaceutical forms
    Concentrate and solvent for solution for injection
    Routes of administration
    Intravenous use
    Dosage and administration details
    50 IU FVIII/kg BW (body weight)

    Investigational medicinal product name
    Kogenate FS
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate and solvent for solution for injection
    Routes of administration
    Intravenous use
    Dosage and administration details
    50 IU FVIII/kg BW (body weight)

    Arm title
    Human-cl rhFVIII (on-demand treatment of bleeding episodes)
    Arm description
    Patients who completed cross-over PK phase were followed up for a period of at least 50 exposure days (EDs) and at least 6 months and treated with Human-cl rhFVIII in case of a bleeding episode.
    Arm type
    Experimental

    Investigational medicinal product name
    Human-cl rhFVIII
    Investigational medicinal product code
    Other name
    Nuwiq
    Pharmaceutical forms
    Concentrate and solvent for solution for injection
    Routes of administration
    Intravenous use
    Dosage and administration details
    On-demand treatment: The Human-cl rhFVIII dosage (and duration) for the treatment of spontaneous or traumatic BEs depended on the location and extent of bleeding and on the clinical situation of the patient. Dosage recommendations were given for minor, moderate and major haemorrhage.

    Number of subjects in period 1
    Human-cl rhFVIII vs. Kogenate FS (PK cross-over) Human-cl rhFVIII (on-demand treatment of bleeding episodes)
    Started
    22
    22
    Completed
    22
    21
    Not completed
    0
    1
         Lost to follow-up
    -
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Overall trial
    Reporting group description
    -

    Reporting group values
    Overall trial Total
    Number of subjects
    22 22
    Age categorical
    Units: Subjects
        Adolescents (12-17 years)
    2 2
        Adults (18-64 years)
    19 19
        From 65-84 years
    1 1
    Gender categorical
    Units: Subjects
        Female
    0 0
        Male
    22 22

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Human-cl rhFVIII vs. Kogenate FS (PK cross-over)
    Reporting group description
    After a FVIII wash-out period of at least 96 hours, subjects received either Human-cl rhFVIII or Kogenate FS (according to the randomisation scheme) for the first PK cycle and the other FVIII product for the second PK cycle. A dose of 50 IU FVIII /kg BW (labelled potency) was administered. PK blood samples for the determination of FVIII levels were taken before and at 0.25, 0.5, 0.75, 1, 3, 6, 9, 12, 24, 30 and 48 hours after the end of the injection.

    Reporting group title
    Human-cl rhFVIII (on-demand treatment of bleeding episodes)
    Reporting group description
    Patients who completed cross-over PK phase were followed up for a period of at least 50 exposure days (EDs) and at least 6 months and treated with Human-cl rhFVIII in case of a bleeding episode.

    Subject analysis set title
    PK-PP Population
    Subject analysis set type
    Per protocol
    Subject analysis set description
    All randomised subjects who completed Phase I of the trial receiving both treatments without significantly violating the inclusion/exclusion criteria or other aspects of the protocol considered to potentially affect the PK results. The PK-PP population refers to the initial cross-over part of the trial.

    Primary: AUC norm (FVIII:C) for Human-cl rhFVIII and Kogenate FS (Chromogenic assay)

    Close Top of page
    End point title
    AUC norm (FVIII:C) for Human-cl rhFVIII and Kogenate FS (Chromogenic assay) [1]
    End point description
    End point type
    Primary
    End point timeframe
    at the end of the study
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: A formal statistical procedure was done to test whether the ratio of mean AUCnorm is within the 0.8 to 1.25 range. The ratio of geometric means [90% CI] for AUCnorm (Human-cl rhFVIII relative to Kogenate FS) was 0.98 [0.874, 1.107].
    End point values
    PK-PP Population
    Number of subjects analysed
    22
    Units: h*IU/mL (IU/kg)
    arithmetic mean (standard deviation)
        Human-cl rhFVIII
    0.39 ( 0.14 )
        Kogenate FS
    0.38 ( 0.09 )
    No statistical analyses for this end point

    Primary: AUC norm (FVIII:C) for Human-cl rhFVIII and Kogenate FS (One-stage assay)

    Close Top of page
    End point title
    AUC norm (FVIII:C) for Human-cl rhFVIII and Kogenate FS (One-stage assay) [2]
    End point description
    End point type
    Primary
    End point timeframe
    at the end of the study
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: A formal statistical procedure was done to test whether the ratio of mean AUCnorm is within the 0.8 to 1.25 range. The ratio of geometric means [90% CI] for AUCnorm (Human-cl rhFVIII relative to Kogenate FS) was 0.97 [0.859, 1.088].
    End point values
    PK-PP Population
    Number of subjects analysed
    22
    Units: h*IU/mL/(IU/kg)
    arithmetic mean (standard deviation)
        Human-cl rhFVIII
    0.37 ( 0.11 )
        Kogenate FS
    0.38 ( 0.1 )
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    AE were reported throughout the whole study. 24 hours SAE reporting requirement. Waiver from 24 hours SAE reporting: hospitalization for the treatment of a (disease-related) BE assessed as unrelated to IMP treatment.
    Adverse event reporting additional description
    All SAEs, whether suspected to be related to study treatment or not, are reported by telephone, fax or e-mail immediately to the responsible Clinical Project Manager, study monitor, or to the responsible local CRO. AEs were evaluated at each patient visit.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    15.1
    Reporting groups
    Reporting group title
    Safety anaylsis population SAF
    Reporting group description
    All patients who received at least one dose of Human-cl rhFVIII.

    Serious adverse events
    Safety anaylsis population SAF
    Total subjects affected by serious adverse events
         subjects affected / exposed
    2 / 22 (9.09%)
         number of deaths (all causes)
    0
         number of deaths resulting from adverse events
    0
    Nervous system disorders
    Hepatic encephalopathy
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hepatobiliary disorders
    Hepatic cirrhosis
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Psychiatric disorders
    Depression suicidal
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 4.5%
    Non-serious adverse events
    Safety anaylsis population SAF
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    11 / 22 (50.00%)
    Investigations
    Protein urine present
         subjects affected / exposed
    2 / 22 (9.09%)
         occurrences all number
    2
    Blood glucose increased
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Platelet count decreased
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    urine keton body present
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Surgical and medical procedures
    Artificial crown procedure
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Dental care
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Nervous system disorders
    Headache
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Hepatic encephalopathy
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Hypoaesthesia
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Neuropathy peripheral
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Paraesthesia
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Tremor
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    General disorders and administration site conditions
    Chills
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Oedema peripheral
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Pyrexia
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Unevaluable event
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Ear and labyrinth disorders
    Ear congestion
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Hypoacusis
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    2 / 22 (9.09%)
         occurrences all number
    2
    Abdominal pain
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Ascites
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Constipation
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Vomiting
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Hepatobiliary disorders
    Hepatic cirrhosis
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Dyspnoea
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Oropharyngeal pain
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Sinus congestion
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Skin and subcutaneous tissue disorders
    Rash
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Psychiatric disorders
    Depression suicidal
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Musculoskeletal and connective tissue disorders
    Muscle tightness
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Musculoskeletal chest pain
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Periarthritis
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Infections and infestations
    Impetigo
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Nasopharyngitis
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Onychomycosis
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    Tooth abscess
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1
    viral upper respiratory tract infection
         subjects affected / exposed
    1 / 22 (4.55%)
         occurrences all number
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    16 Mar 2010
    Protocol version 07, dated 16-MAR-2010 included amendments 1-3, which had been made before the study started.
    13 Dec 2010
    Protocol Amendment 04: Number of study centres and participating countries was updated due to the addition of new study centres in Germany and Bulgaria.
    13 Apr 2011
    Amendment 05: Update of planned clinical study end. Change in address of Coordinating Investigator. Addiition of higher strengths of Human-cl rhFVIII Clarification of FVIII washout period prior to screening. Clarification regarding prophylactic treatments following a major surgery or certain major bleeding episodes. Update of drug supply management logistics. Clarification regarding recording of source data. Clarification regarding documentation of bleeding episodes occurring simultaneously at several sites. Update on statistical section on efficacy of the on-demand treatment. Documentation of Bleeding Episodes Occurring Simultaneously at Several Sites Statistical Analysis of Efficacy of On-Demand Treatment
    05 Jul 2012
    Amendment 06: Date for Termination of Clinical Study Address of Coordinating Investigator Responsibility for Drug Shipment to Study Centers Analysis of Inhibitor Rate

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 17:11:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA